Table 2.

Baseline characteristics of nab-paclitaxel initiators by line of therapy^a

Characteristic	First line (n = 172)		Second line (n = 211)		Third line or later (n = 281)		All (N = 664)
	n	%	n	%	n	%	n	%
Age
≤ 39 y	4	2.3	7	3.3	16	5.7	27	4.1
40–49 y	36	20.9	53	25.1	64	22.8	153	23.0
50–59 y	53	30.8	78	37.0	116	41.3	247	37.2
60–69 y	58	33.7	60	28.4	66	23.5	184	27.7
≥ 70 y	21	12.2	13	6.2	19	6.8	53	8.0
Geographic area
Midwest	39	22.7	47	22.3	65	23.1	151	22.7
Northeast	12	7.0	11	5.2	25	8.9	48	7.2
South	91	52.9	123	58.3	146	52.0	360	54.2
West	30	17.4	30	14.2	45	16.0	105	15.8
Healthcare utilization
No. of physician visits
0	0	0	0	0	0	0	0	0
1–2	2	1.2	2	0.9	3	1.1	7	1.1
≥ 3	170	98.8	209	99.1	278	98.9	657	98.9
No. of emergency department visits
0	103	59.9	117	55.5	190	67.6	410	61.7
1–2	51	29.7	82	38.9	72	25.6	205	30.9
≥ 3	18	10.5	12	5.7	19	6.8	49	7.4
No. of hospitalizations
0	119	69.2	138	65.4	196	69.8	453	68.2
1–2	47	27.3	68	32.2	77	27.4	192	28.9
≥ 3	6	3.5	5	2.4	8	2.8	19	2.9
	Median	IQR	Median	IQR	Median	IQR	Median	IQR
Length of health plan membership, y	2.6	(1.4–4.2)	1.9	(1.0–3.0)	2.7	(1.7–4.0)	2.4	(1.4–3.7)
Length of inpatient stay, db	5.0	(3.0–13.0)	4.0	(2.0–9.0)	5.0	(2.0–8.0)	5.0	(2.0–9.0)

IQR interquartile range

^aData are from the Optum Research Database, January 1, 2005 to September 30, 2012

^bAmong those with ≥ 1 hospital stay